PTGS2 and nephrotic syndrome: The use of selective cyclooxygenase-2 (COX-2) inhibitors was not associated with a higher risk of nephrotic syndrome, although there was not a statistically significant trend among patients with a past use, in contrast to conventional NSAIDs.